FDA grants Fast Track status to OKYO Pharma's urcosimod for treating neuropathic corneal pain.

OKYO Pharma's drug urcosimod has received Fast Track designation from the FDA for treating neuropathic corneal pain (NCP), a severe eye condition lacking approved treatments. The designation aims to speed up the drug's development and review process, potentially offering earlier access to patients with this painful condition. This move highlights the drug's potential to address an unmet medical need.